News & Updates

In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.

IMD is a serious and life-threatening fungal infection and its clinical manifestations are like bacterial pneumonia. Patients with prolonged neutropenia, chronic obstructive pulmonary disease (COPD) or severe viral infection, HIV and CMV reactivation, uncontrolled diabetes mellitus, liver and solid tumors and receiving organ transplant are at risk of developing IMD. Early recognition of the disease and providing life-saving treatment will significantly reduce the mortality and improve patient outcomes. To learn more about Fungal Disease Awareness, please view the video and click this link: https://ph-mims.com/fdaw2020.

The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.

Transurethral water vapour thermal therapy (WVTT) delivered in an office-based setting under local anaesthesia alone is an effective and safe alternative for surgical treatment of benign prostatic hyperplasia (BPH) in Chinese patients, researchers from the Chinese University of Hong Kong (CUHK) have reported.